Sadly, terrorism is a real threat to the United States homeland as we just saw last week. However, we can take a little solace in the fact that the recent terrorist attack involved crude homemade non-radiological bombs. The fact remains…
Tag: pharma
Weekend update with some charts, Market forecast and opinion. (VIDEO)
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
Valeant Acquires Obagi, Which Biotechs Are Next?
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that…
Download $TSRX Analyst Report
Download Analyst Report on $TSRX HERE-TSRX-SunTrust-Robinson-Humphrey-Feb-12
Why the latest rally could be a bull trap
This week has been a strange market week for sure. I have held back on picks mainly because I want to see some clarity as I believe we are at a market top, and economic data has peaked out. Furthermore,…
GLOBE NEWSWIRE: Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem’s PLacental eXpanded (PLX) cells orphan drug status…
Pozen: An Undervalued Investment And Catalyst Trade Opportunity
Small cap biopharmas that make for good long term investments are hard to find. Most small cap biopharmas burn a ton of cash while developming treatments for a variety of ailments and rare diseases. Today, we focus on Pozen (NASDAQ:POZN)…
Weekend Update: $CORT $ATHX $CLSN $BLRX $NEPT + Chart Analysis And Explanation
In this video, I review a couple of charts, and review a couple of my trade calls. Chart analysis and explanation offered. Hope you find the video educational! Scott
Athersys: Upcoming Short Term Catalyst With Promising Longer Term Potential
In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward. Last July, I wrote about Pluristem Therapeutics (PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products…
